Emily Proano Emily Proano

How Machine Learning and Porcine Tissue Models Are Revolutionizing Medication Safety

Navigating the complexities of multiple medications can be overwhelming, especially when considering potential drug interactions. Recent advancements in drug research are addressing these concerns by combining porcine tissue models with machine learning to predict drug interactions more accurately. This innovative approach aims to enhance medication safety and efficacy, potentially simplifying treatment plans for patients.

Read More
Emily Proano Emily Proano

A Breakthrough for Veterans with Traumatic Brain Injuries

Stanford Medicine’s latest discovery reveals ibogaine, a plant-based psychoactive drug, as a groundbreaking treatment for traumatic brain injuries in veterans. Offering dramatic improvements in PTSD, depression, and anxiety, this study highlights ibogaine’s potential to heal invisible wounds and restore hope to those who have served.

Read More
Emily Proano Emily Proano

Mid Old Cells Hold the Key to Anti Aging

Researchers have discovered mid-old cells, an intermediate stage between youthful and senescent cells, which contribute to aging and inflammation. Targeting these cells with therapies like SLIT2 protein offers a promising new approach to reversing age-related tissue damage and dysfunction.

Read More
Emily Proano Emily Proano

Ginger May Hold the Key to Reducing Autoimmune Inflammation

Ginger shows promise in reducing harmful immune responses in autoimmune diseases like lupus and APS. By calming neutrophils and curbing inflammation, this natural remedy could offer a safe, accessible way to support better health alongside conventional treatments.

Read More
Emily Proano Emily Proano

Screen Time and Developmental Delays in Young Children

Excessive screen time at age 1 is linked to developmental delays in communication and problem-solving at ages 2 and 4, a study finds. Limiting screen exposure and promoting real-world interaction can support healthy early childhood development.

Read More
Emily Proano Emily Proano

Donanemab Shows Promise in Slowing Alzheimer’s Progression

Donanemab, a monoclonal antibody targeting amyloid plaques, significantly slowed Alzheimer’s progression in a major trial. By preserving cognition and daily function, it offers new hope for early Alzheimer’s patients, despite some risks like amyloid-related imaging abnormalities.

Read More
Emily Proano Emily Proano

Detecting Parkinson’s Through Nighttime Breathing Patterns

New research reveals how nighttime breathing patterns can uncover Parkinson’s disease with remarkable accuracy, even years before diagnosis. This non-invasive breakthrough not only enables earlier detection but also tracks symptom progression, promising a transformative approach to managing Parkinson’s worldwide.

Read More
Emily Proano Emily Proano

Early Intervention for Autism: The Promising Impact of Preemptive Care on Developmental Outcomes

Preemptive intervention for infants showing early signs of autism offers hope for reshaping developmental outcomes. A groundbreaking study found that targeted caregiver-infant interactions reduced autism symptom severity and halved diagnostic rates by age three. This transformative approach highlights the power of early action in enhancing language, social skills, and caregiver confidence, paving the way for brighter futures.

Read More